Clinical Trials Browser

Solid Tumors × pembrolizumab × 30 days × Clear all

NCT05101070 2026-03-18

aCCeleR8-001

Phase 1/2 Recruiting

Other solid neoplasm

Solid Tumors

NCT03313778 2026-03-04

KEYNOTE-603

Phase 1 Active not recruiting

Other solid neoplasm

Solid Tumors